Eli Lilly Acquires Centessa Pharmaceuticals for $6.3 Billion

Eli Lilly and Company is set to acquire Centessa Pharmaceuticals in a transaction valued at $6.3 billion. The acquisition received final approval from the High Court of Justice of England and Wales, marking a significant step towards closing. This acquisition is structured as a Court-sanctioned scheme of arrangement under English law.

Under the terms of the acquisition, Eli Lilly will pay $38.00 in cash per Centessa share. Additionally, shareholders will receive a contingent value right (CVR) that could yield further payments contingent on the achievement of certain milestones. The effectiveness of the scheme is anticipated to occur imminently, with the final court order expected to be delivered on June 24, 2026. Consequently, trading of Centessa’s American Depositary Shares on Nasdaq is slated to cease before the market opens on that day.

Eli Lilly's strategic rationale behind acquiring Centessa lies in bolstering its pipeline with Centessa’s innovative treatments, particularly for neurological conditions like excessive daytime sleepiness. Centessa, a clinical-stage firm, fits within Lilly’s broader strategy of expanding its therapeutic portfolio, thus enhancing its position in the pharmaceuticals sector by focusing on novel high-potential treatments.

For the broader pharmaceuticals market, the acquisition highlights ongoing competitive consolidation, as major players like Eli Lilly seek to acquire innovative biotech firms to remain at the forefront of drug development. This move underscores a trend where large pharmaceutical companies are increasingly looking beyond internal R&D efforts, opting instead to acquire promising external candidates to address market needs and fuel long-term growth.

Looking ahead, the closing of this transaction awaits the administrative procedure of court order delivery to the Registrar of Companies. Attention will now turn to the performance of the CVR milestones, which could impact the final disbursement to Centessa shareholders. This acquisition also reflects Lilly’s strategic focus on diversifying its drug offerings, potentially prompting similar strategies among other pharmaceutical giants aiming to achieve competitive advantage.